Cargando…
ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138777/ https://www.ncbi.nlm.nih.gov/pubmed/31482389 http://dx.doi.org/10.1245/s10434-019-07611-5 |
| _version_ | 1783518621862985728 |
|---|---|
| author | Francken, Anne Brecht Hoekstra-Weebers, Josette E. H. M. Deckers, Eric Hoekstra, Harald J. |
| author_facet | Francken, Anne Brecht Hoekstra-Weebers, Josette E. H. M. Deckers, Eric Hoekstra, Harald J. |
| author_sort | Francken, Anne Brecht |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7138777 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71387772020-04-14 ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified Francken, Anne Brecht Hoekstra-Weebers, Josette E. H. M. Deckers, Eric Hoekstra, Harald J. Ann Surg Oncol ASO Author Reflections Springer International Publishing 2019-09-03 2020 /pmc/articles/PMC7138777/ /pubmed/31482389 http://dx.doi.org/10.1245/s10434-019-07611-5 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | ASO Author Reflections Francken, Anne Brecht Hoekstra-Weebers, Josette E. H. M. Deckers, Eric Hoekstra, Harald J. ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified |
| title | ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified |
| title_full | ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified |
| title_fullStr | ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified |
| title_full_unstemmed | ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified |
| title_short | ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified |
| title_sort | aso author reflections: stage-adjusted reduced follow-up of melanoma patients is justified and cost effective, until biomarkers to predict prognosis have been identified |
| topic | ASO Author Reflections |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138777/ https://www.ncbi.nlm.nih.gov/pubmed/31482389 http://dx.doi.org/10.1245/s10434-019-07611-5 |
| work_keys_str_mv | AT franckenannebrecht asoauthorreflectionsstageadjustedreducedfollowupofmelanomapatientsisjustifiedandcosteffectiveuntilbiomarkerstopredictprognosishavebeenidentified AT hoekstraweebersjosetteehm asoauthorreflectionsstageadjustedreducedfollowupofmelanomapatientsisjustifiedandcosteffectiveuntilbiomarkerstopredictprognosishavebeenidentified AT deckerseric asoauthorreflectionsstageadjustedreducedfollowupofmelanomapatientsisjustifiedandcosteffectiveuntilbiomarkerstopredictprognosishavebeenidentified AT hoekstraharaldj asoauthorreflectionsstageadjustedreducedfollowupofmelanomapatientsisjustifiedandcosteffectiveuntilbiomarkerstopredictprognosishavebeenidentified |